STVN
Overvalued by 181.5% based on the discounted cash flow analysis.
Market cap | $5.17 Billion |
---|---|
Enterprise Value | $5.55 Billion |
Dividend Yield | $0.06 (0.305745914602003%) |
Earnings per Share | $0.54 |
Beta | 0.58 |
Outstanding Shares | 272,789,169 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 38.48 |
---|---|
PEG | 93.99 |
Price to Sales | 5.87 |
Price to Book Ratio | 4.7 |
Enterprise Value to Revenue | 4.93 |
Enterprise Value to EBIT | 28.27 |
Enterprise Value to Net Income | 44 |
Total Debt to Enterprise | 0.08 |
Debt to Equity | 0.33 |
No data
No data
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end por...